{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"PCSK9 Inhibitors Required to Reach LDL-C Goals in Many High-risk Patients - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"5sTzrcaFpV\"><a href=\"https:\/\/themedicalxchange.com\/en\/2016\/09\/08\/european-society-of-cardiology-esc-congress-2016\/\">PCSK9 Inhibitors Required to Reach LDL-C Goals in Many High-risk Patients<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/2016\/09\/08\/european-society-of-cardiology-esc-congress-2016\/embed\/#?secret=5sTzrcaFpV\" width=\"600\" height=\"338\" title=\"&#8220;PCSK9 Inhibitors Required to Reach LDL-C Goals in Many High-risk Patients&#8221; &#8212; The Medical Xchange\" data-secret=\"5sTzrcaFpV\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2016\/09\/2362_ESC_2016_EN_Fig_1.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"Rome \u2013 To reach new low-density lipoprotein cholesterol (LDL-C) targets of 50% reduction from baseline in high-risk patients, PCSK9 inhibition may frequently be the only option, according to data presented at the ESC 2016 meeting. It is now clear that many of those at highest risk of a cardiovascular (CV) event, such as those with established CV disease or familial hypercholesterolemia (FH), are not optimally protected even when maximum doses of statins, ezetimibe, and other oral therapies are acceptably tolerated."}